West Pharmaceutical Services filed a Worker Adjustment and Retraining Notification with the Indiana Department of Workforce Development informing the agency that it will to close the company’s Frankfort, Indiana contract manufacturing facility.
According to the filing, “virtually all employees employed primarily at the Frankfort plant will be terminated.”
Terminations are expected to commence October 1, 2018.
According to second-quarter 2018 results released in July, net sales of $447.5 million grew 12.6% over the prior-year quarter. At constant currency, organic sales growth was 9.0%.
"This is part of a restructuring program that our Company announced in February to help streamline our manufacturing plant network and enable us to operate more efficiently and align our focus towards healthcare-related diagnostic and pharmaceutical products," according to a statement from Eric Haman, Director of Global Corporate Communications for West Pharmaceutical. "While this transition won’t happen until closer to the end of this year, we made the announcement to our employees earlier in the year, as we wanted to give our team plenty of time to understand and plan for this. We currently have fewer than 60 employees in Frankfort who will be impacted. We are closely working with all impacted team members through this transition and will be offering relocation packages to those employees who are interested in relocating and who have the required skills and experiences to fill open roles across the West network, as we expect job opportunities to grow overall at West in 2018, as they did in 2017. In addition, West will be offering generous severance and outplacement services to care for and help in the transition for our employees who will no longer have a role within West."